Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VGNX -- Variagenics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (71)	10/19/2001 2:30:18 PM
From: keokalani'nui	Read Replies (2) \| Respond to of 269

One can get into the Miami aacr abstracts now. Go to the 2001 AACR-NCI-EORTC International Conference. Abstract P804 (though not using vgnx's technology) really caught my attention as demonstrating where vgnx's technology can go. Read it yourself, but basically gene expression profiling of B-cell lymphoma shows a couple different diseases and that stratified patients had strikingly different responses to chemotherapy, like 75% of one group was cured by chemotherapy and the other, 25%. Hard to see how this will affect clinical practice immediately, but easy to imagine how it will someday. --Wilder, a recently minted vgnx shareholder. BTW, I've been having fun in the EGFr stuff. (Though they are hiding the ball, the abgx Mab update at the meeting might be interesting. 4 of 4 had skin rash.)